On Friday, Pliant Therapeutics Inc (NASDAQ: PLRX) was -7.60% drop from the session before settling in for the closing price of $3.29. A 52-week range for PLRX has been $2.43 – $18.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -41.09%. When this article was written, the company’s average yearly earnings per share was at -32.09%. With a float of $53.49 million, this company’s outstanding shares have now reached $60.85 million.
Let’s determine the extent of company efficiency that accounts for 158 employees. In terms of profitability, gross margin is 66.96%, operating margin of -4588.47%, and the pretax margin is -4166.96%.
Pliant Therapeutics Inc (PLRX) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Pliant Therapeutics Inc stocks. The insider ownership of Pliant Therapeutics Inc is 12.08%, while institutional ownership is 97.36%. The most recent insider transaction that took place on Jan 17 ’25, was worth 587,150. In this transaction President and CEO of this company sold 52,419 shares at a rate of $11.20, taking the stock ownership to the 430,517 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Financial Officer sold 20,148 for $11.20, making the entire transaction worth $225,680. This insider now owns 262,608 shares in total.
Pliant Therapeutics Inc (PLRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.9 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -32.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.81% during the next five years compared to -22.68% drop over the previous five years of trading.
Pliant Therapeutics Inc (NASDAQ: PLRX) Trading Performance Indicators
You can see what Pliant Therapeutics Inc (PLRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 10.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.34, a number that is poised to hit -0.98 in the next quarter and is forecasted to reach -3.78 in one year’s time.
Technical Analysis of Pliant Therapeutics Inc (PLRX)
Looking closely at Pliant Therapeutics Inc (NASDAQ: PLRX), its last 5-days average volume was 9.49 million, which is a jump from its year-to-date volume of 2.19 million. As of the previous 9 days, the stock’s Stochastic %D was 5.61%. Additionally, its Average True Range was 1.13.
During the past 100 days, Pliant Therapeutics Inc’s (PLRX) raw stochastic average was set at 4.46%, which indicates a significant decrease from 5.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 424.02% in the past 14 days, which was higher than the 178.17% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.64, while its 200-day Moving Average is $12.54. However, in the short run, Pliant Therapeutics Inc’s stock first resistance to watch stands at $3.36. Second resistance stands at $3.67. The third major resistance level sits at $3.86. If the price goes on to break the first support level at $2.86, it is likely to go to the next support level at $2.67. Now, if the price goes above the second support level, the third support stands at $2.36.
Pliant Therapeutics Inc (NASDAQ: PLRX) Key Stats
There are 60,854K outstanding shares of the company, which has a market capitalization of 184.98 million. As of now, sales total 1,580 K while income totals -161,340 K. Its latest quarter income was 0 K while its last quarter net income were -57,760 K.
